Photobiomodulation therapy mitigates cardiovascular aging and improves survival.

Autor: Syed SB; Laboratory of Cardiovascular Sciences, NIA, NIH, Baltimore, Maryland, USA., Ahmet I; Laboratory of Cardiovascular Sciences, NIA, NIH, Baltimore, Maryland, USA., Chakir K; Laboratory of Cardiovascular Sciences, NIA, NIH, Baltimore, Maryland, USA., Morrell CH; Laboratory of Cardiovascular Sciences, NIA, NIH, Baltimore, Maryland, USA., Arany PR; Oral Biology, Surgery, and Biomedical Engineering, University of Buffalo, Buffalo, New York, USA., Lakatta EG; Laboratory of Cardiovascular Sciences, NIA, NIH, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: Lasers in surgery and medicine [Lasers Surg Med] 2023 Mar; Vol. 55 (3), pp. 278-293. Date of Electronic Publication: 2023 Feb 23.
DOI: 10.1002/lsm.23644
Abstrakt: Background: Photobiomodulation (PBM) therapy, a form of low-dose light therapy, has been noted to be effective in several age-associated chronic diseases such as hypertension and atherosclerosis. Here, we examined the effects of PBM therapy on age-associated cardiovascular changes in a mouse model of accelerated cardiac aging.
Methods: Fourteen months old Adenylyl cyclase type VIII (AC8) overexpressing transgenic mice (n = 8) and their wild-type (WT) littermates (n = 8) were treated with daily exposure to Near-Infrared Light (850 nm) at 25 mW/cm 2 for 2 min each weekday for a total dose of 1 Einstein (4.5 p.J/cm 2 or fluence 3 J/cm 2 ) and compared to untreated controls over an 8-month period. PBM therapy was administered for 3.5 months (Early Treatment period), paused, due to Covid-19 restrictions for the following 3 months, and restarted again for 1.5 months. Serial echocardiography and gait analyses were performed at monthly intervals, and serum TGF-β1 levels were assessed following sacrifice.
Results: During the Early Treatment period PBM treatments: reduced the age-associated increases in left ventricular (LV) mass in both genotypes (p = 0.0003), reduced the LV end-diastolic volume (EDV) in AC8 (p = 0.04); and reduced the left atrial dimension in both genotypes (p = 0.02). PBM treatments substantially increased the LV ejection fraction (p = 0.03), reduced the aortic wall stiffness (p = 0.001), and improved gait symmetry, an index of neuro-muscular coordination (p = 0.005). The effects of PBM treatments, measured following the pause, persisted. Total TGF-β1 levels were significantly increased in circulation (serum) in AC8 following PBM treatments (p = 0.01). We observed a striking increase in cumulative survival in PBM-treated AC8 mice (100%; p = 0.01) compared to untreated AC8 mice (43%).
Conclusion: PBM treatment mitigated age-associated cardiovascular remodeling and reduced cardiac function, improved neuromuscular coordination, and increased longevity in an experimental animal model. These responses correlate with increased TGF-β1 in circulation. Future mechanistic and dose optimization studies are necessary to assess these anti-aging effects of PBM, and validation in future controlled human studies is required for effective clinical translation.
(© 2023 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.)
Databáze: MEDLINE
Externí odkaz: